A variety of monoclonal antibodies reactive with colorectal tumour associated antigens have been described (Steplewski et al., 1982; Herlyn et al., 1979; Lindholm et al., 1983; Durrant et al., 1986a) . However, one problem that needs to be solved before monoclonal antibodies can be used effectively for imaging or therapy is the heterogeneity of cell surface antigen expression on tumours (Durrant et al., 1986a; Brattain et al., 1981; Dexter et al., 1981 tissues (Embleton et al., 1981; Price et al., 1983a, b). It has been used extensively for colorectal tumour imaging (Farrands et al., 1982; Armitage et al., 1983) and linked to ricin A chain has been screened in a phase 1 clinical trial (Byers et al., 1989) . 228 recognises carcinoembryonic antigen and not normal cross-reacting antigen. Its main normal reactivity is with secretory components of the gastrointestinal tract. It has also been shown to localise in tumours of colorectal cancer patients (Pimm et al., 1986) . 161 antibody also recognises CEA but also cross-reacts with NCA. It therefore binds to a number of normal tissues, including liver and kidney tissues and would therefore be of limited clinical value. C14 recognises the Y haptenic blood group antigen which is expressed widely on colorectal cancers and adenomas (Lloyd et al., 1983; Brown et al., 1984; Abe et al., 1986; Durrant et al., 1986a, b; Ernst et al., 1986) . Its main reactivity with normal tissues is restricted to secretory epithelial tissues in individuals who secrete blood group substances (Brown et al., 1984 Our results indicate that more colorectal cancers were recognised and the intensity of staining was increased by using combinations of monoclonal antibodies when compared to a single antibody.
A variety of monoclonal antibodies reactive with colorectal tumour associated antigens have been described (Steplewski et al., 1982; Herlyn et al., 1979; Lindholm et al., 1983; Durrant et al., 1986a) . However, one problem that needs to be solved before monoclonal antibodies can be used effectively for imaging or therapy is the heterogeneity of cell surface antigen expression on tumours (Durrant et al., 1986a; Brattain et al., 1981; Dexter et al., 1981) . Variation in antigen expression and density on individual tumour cells from primary and metastatic tumours could account in part for the difficulties in detecting all known lesions in vivo using a single radiolabelled monoclonal antibody and could lead to escape from the cytotoxic effects of a single monoclonal antibody-drug conjugate. One approach to these problems is to use a combination of mono clonal antibodies which recognise distinct surface antigens and/or epitopes covering the range of heterogeneous antigen expression.
Although this is not a new concept very few studies have been published showing that combinations of antibodies recognise a larger number of primary tumours. Most studies have used either cell lines or human xenografts, neither of which has the heterogeneity observed in human tumours. Our early studies (Durrant et al., 1986a) showed that it was necessary to analyse at least 50 individual colorectal tumours to obtain a clear picture of tumour phenotypes as the intertumour variation was so diverse. In this report we compared the binding of a panel of anti-colorectal monoclonal antibodies reactive with different 'tumour associated' epitopes singly and in combinations, to colorectal tumour cells.
The monoclonal antibodies have been selected because they bind preferentially to tumour cells compared to a panel of normal tissues as assayed by immunocytochemical staining of cryopreserved tissues. 791T/36 recognises a glycoprotein of molecular weight 72,000 which is expressed on colorectal osteosarcoma and ovarian tumours. Its main reactivity with normal tissues is with activated T lymphocytes and stromal Correspondence: L.G. Durrant. Received 27 January 1989; and in revised form 6 June 1989.
tissues (Embleton et al., 1981; Price et al., 1983a, b) . It has been used extensively for colorectal tumour imaging (Farrands et al., 1982; Armitage et al., 1983) and linked to ricin A chain has been screened in a phase 1 clinical trial (Byers et al., 1989) . 228 recognises carcinoembryonic antigen and not normal cross-reacting antigen. Its main normal reactivity is with secretory components of the gastrointestinal tract. It has also been shown to localise in tumours of colorectal cancer patients (Pimm et al., 1986) . 161 antibody also recognises CEA but also cross-reacts with NCA. It therefore binds to a number of normal tissues, including liver and kidney tissues and would therefore be of limited clinical value. C14 recognises the Y haptenic blood group antigen which is expressed widely on colorectal cancers and adenomas (Lloyd et al., 1983; Brown et al., 1984; Abe et al., 1986; Durrant et al., 1986a, b; Ernst et al., 1986) . Its main reactivity with normal tissues is restricted to secretory epithelial tissues in individuals who secrete blood group substances (Brown et al., 1984 Our results indicate that more colorectal cancers were recognised and the intensity of staining was increased by using combinations of monoclonal antibodies when compared to a single antibody.
Materials and methods

Tumour cells
Cell suspensions were prepared from tissue of 50 individual tumours within 18 h of removal. Tissue was finely minced and disaggregated in 0.05% collagenase (Boehringer, Mannheim, FR Germany) as previously described (Durrant et al., 1986a) . This collagenase had no effect on antigen expression on cultured cell lines. The clinicopathology of these tumours is shown in Table I. Monoclonal antibodies Antibodies to tumour associated antigens A panel of murine monoclonal antibodies were used in this study. 791T/36 is an IgG2b monoclonal antibody which recognises the 791T p72 antigen found in many carcinomas (Embleton et al., 1981; Price et al., 1983) . C14 is an IgM monoclonal antibody which recognises the Y haptenic blood group antigen expressed by the majority of colon adenocarcinomas (Brown et al., 1983) . 161 is an IgG, monoclonal antibody that recognises a similar epitope expressed on CEA and NCA (Price et al., 1987) . Finally, 228 monoclonal antibody recognised an epitope only expressed on CEA (Price et al., 1987 (Makin et al., 1984) .
Indirect immunofluorescence Cells were washed twice in Hank's balanced salt solution (HBSS) and stained by indirect immunofluorescence as previously described (Durrant et al., 1986a, b Extranuclear membrane preparations Fresh surgically resected colorectal adenocarcinomas or normal colonic mucosa were homogenised in a buffer containing 1 mM NaHCO3, 2 mM CaCl2, 2 mM MgC12, 1 mM phenylmethylsulphonyl fluoride pH 7.6 (4 vol. of buffer per g of tissue) to prepare a crude membrane preparation as described previously (Brown et al., 1983) . Membranes were prepared from 12 individual tumours. The clinicopathology of these tumours is shown in Table I . Analysis of the binding of a panel of monoclonal antibodies, recognising tumour associated antigens, to a series of disaggregated colorectal tumours illustrates the inter-tumour variation in intensity of staining (Figure 1 ) and the intra-tumour variation in the percentage of cells expressing the relevant antigens (Figure 2) .
All of the monoclonal antibodies recognising tumour associated antigens stained the majority of tumours with a moderate intensity (MLFs of 122-1,000). However, monoclonal antibody 161 stained the most tumours (36%) with strong intensity (MLF> 1,000 Table III. C14 monoclonal antibody bound with the strongest intensity when compared to 791T/36 (P<0.01) or to 288 (P<0.05). However, a combination of C14 and 228 stained significantly stronger than either C14 (P<0.01) or 228 (P<0.01). Furthermore the combination stained all of the membranes. The addition of 791T/36 failed to significantly increase the intensity of staining seen with C14 and/or 228. Of particular interest was the tumour (T8) which only stained weakly with the monoclonal antibody C14 and failed to stain significantly above background with the monoclonal 98 (80) antibodies 228 and 791T/36. All the combinations bound significantly but a combination of 228 and C14 bound 2.2 times more strongly than C14 alone. None of the combinations significantly stained autologous normal membranes.
Discussion
Murine monoclonal antibodies directed against tumour associated antigens are potentially useful for both tumour diagnosis and therapy. However, previous studies have shown qualitative differences in tumour associated antigen expression between tumours (Durrant et al., 1986; Ballantyne et al., 1986; Spremulli et al., 1983) and within a tumour (Durrant et al., 1986b; Petricciani, 1982) . Furthermore, the level of antigen expression on individual cells within a tumour varies enormously (Durrant et al., 1986b (Durrant et al., 1986a) and was chosen as the most suitable analysis for this study.
Inter-tumour heterogeneity was completely abrogated by using a combination of the monoclonal antibodies, 791T/36, 228, C14 and 161, as all 50 tumours studied were stained by one or more of these monoclonal antibodies. This combination excluding the monoclonal antibody 161 which recognises CEA but cross-reacts with NCA and therefore stains normal colon and granulocytes, recognised 49 of the 50 tumours analysed. Ninety-eight per cent of these lesions would therefore be recognised by this simple combination of three antibodies. Similarly, although both 228 and C14 recognised 92% of the tumour extranuclear membranes, a combination of both antibodies bound significantly to 100% of the membranes.
Monoclonal antibodies 791T/36 and 228 have been used for diagnostic imaging of colorectal cancer (Armitage et al., 1983; Pimm et al., 1986) . As C14 is an IgM antibody its molecular size precludes efficient localisation in tumour. However, these studies clearly show that the Y hapten is an extremely important colorectal tumour associated antigen and that an IgG variant of C14 may be clinically valuable. To reduce non-specific toxicity the optimal drug delivery system requires cleavage of the drug after the conjugate has bound to the tumour associated antigen and internalised. The majority of large molecules are transported by constitutive pinocytosis (Besterman & Low, 1983) . Both 791T/36 and 228 monoclonal antibodies enter tumour cells by this route (Garnett et al., 1986b; Byers et al., 1988) . There is no reason to assume C14 antibody will not be internalised by a similar mechanism. The antigen density per cell is very important as it will determine the number of molecules of conjugate internalised. An MLF of 1,000 approximately corresponds to (Casellas et al., 1984) could be conjugated to antibody or more molecules of a drug could be attached via a carrier to each antibody molecule (Garnett & Baldwin, 1986) . The disadvantage of the latter two methods is that if the tumour associated antigen is only expressed weakly on normal cells sufficient drug will accumulate to cause cytotoxicity.
The intensity of staining tumour membranes was increased without significant binding to autologous normal colon membranes using combinations of either 228 and C14 or of 228, C14 and 791T/36 when compared to binding of each individual monoclonal antibody. In fact, one tumour which failed to bind significantly to any single monoclonal antibody stained significantly with a combination of 228 and C14. Similar in vitro studies in our laboratory have shown that two high affinity anti-CEA antibodies, 198 and B14/B8, potentiated the binding of 228 monoclonal antibody to the surface of MKN45 cells by increasing the dwell time of the cell bound antibody. This in turn led to increased endocytosis of the antibody and when 228 was linked to ricin A chain produced enhanced cytotoxicity (Byers et al., 1988) . As the spectrum of antigen expression is different on normal tissues these effects may not be seen on healthy tissue and therefore combinations of monoclonal antibodies may increase the tumour to normal binding ratios. Further studies using FITC labelled monoclonal antibodies to tumour associated antigens, and biotin labelled anticytokeratin antibodies and avidin phycoerythrin to identify epithelial cells will allow direct measurements of any increase in the intensity of staining and the percentage of cells recognised using combinations of antibodies. Krizan et al. (1985) showed that both the relative fluorescence and the percentage of cells recognised was increased when suboptimal doses of three monoclonal antibodies were added to cells rather than saturating concentrations of each monoclonal antibody alone or combined. Perhaps the total dose of monoclonal antibody can be reduced by using combinations. Ceriani et al. (1987) demonstrated that a combination of antibodies recognising different epitopes on the same antigen could increase the therapeutic effect against a relevant human xenograft, but not against an antigen negative xenograft, when compared to single antibody studies.
If combinations of monoclonal antibodies were used clinically these studies predict that all lesions could be recognised and the intensity of staining would be increased but without significant binding to normal colon. This should greatly increase the number of tumours detected by radiolabelled antibodies and increase the therapeutic effectiveness of monoclonal antibody drug conjugates.
